TY - JOUR
T1 - Recommended configuration for personal health records by standardized data item sets for diabetes mellitus and associated chronic diseases
T2 - a report from a collaborative initiative by six Japanese associations
AU - Nakashima, Naoki
AU - Noda, Mitsuhiko
AU - Ueki, Kohjiro
AU - Koga, Tatsuhiko
AU - Hayashi, Michio
AU - Yamazaki, Katsuya
AU - Nakagami, Tomoko
AU - Ohara, Makoto
AU - Gochi, Akira
AU - Matsumura, Yasushi
AU - Kimura, Michio
AU - Ohe, Kazuhiko
AU - Kang, Dongchon
AU - Toya, Yoshiyuki
AU - Yamagata, Kunihiro
AU - Yokote, Koutaro
AU - Ikeda, Shunya
AU - Mitsutake, Naohiro
AU - Yamamoto, Ryuichi
AU - Tanizawa, Yukio
N1 - Funding Information:
Conflict of interest Naoki Nakashima has received research grants from Fujitsu Ltd. Kohjiro Ueki has received honoraria for lectures from Astellas Pharma Inc., AstraZeneca Co., Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly Japan Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Co. Ltd., MSD Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co. Ltd, Sanofi Aventis Co. Ltd, Shionogi & Co. Ltd., Sumitomo Dainippon Co. Ltd, Taisho Toyama Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co Ltd., and research grants from Astellas Pharma Inc. He has also received scholarship grants from Astellas Pharma Inc, Daiichi Sankyo Co. Ltd., Eli Lilly Japan Co. Ltd., Kowa Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma Co. Ltd., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co. Ltd., Sanofi Aventis Co. Ltd., Sumitomo Dainip-pon Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co Ltd. Koutaro Yokote has received honoraria for lectures from Astellas Pharma Inc., Astellas Amgen BioPharma Co. Ltd., AstraZeneca Co., Ltd., MSD Co. Ltd., Ono Pharmaceutical Co. Ltd., Sanwa Kagaku Kenkyusho Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Kowa Co. Ltd., Kowa Pharmaceutical Co., Ltd, Sanofi Aventis Co. Ltd., Shionogi & Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co Ltd., Mitsubishi Tanabe Co. Ltd., Daiichi Sankyo Co. Ltd., Sumitomo Dainippon Co. Ltd., Eli Lilly Japan Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma Co. Ltd., Novo Nordisk Pharma Ltd., Pfizer Japan Inc., and Mochida Pharmaceutical Co. Ltd., and research grants from Astellas Pharma Inc. He has also received scholarship grants from Astellas Pharma Inc., MSD Co. Ltd., Ono Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Mitsubishi Tanabe Co. Ltd., Teijin Pharm Ltd., Daiichi Sankyo Co. Ltd., Sumitomo Dainippon Co. Ltd., Eli Lilly Japan Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novo Nordisk Pharma Ltd., Pfizer Japan Inc., and Mochida Pharmaceutical Co. Ltd., and a course endowed by MSD Co. Ltd. Mitsuhiko Noda, Tatsuhiko Koga, Michio Hayashi, Katsuya Yamazaki, Tomoko Nakagami, Makoto Ohara, Akira Gochi, Yasushi Matsumura, Michio Kimura, Kazuhiko Ohe, Dongchon Kang, Yoshiyuki Toya, Kunihiro Yamagata, Shunya Ikeda, Naohiro Mitsutake, Ryuichi Yamamoto, and Yukio Tanizawa have no conflict of interest.
Funding Information:
The article is a report from the Collaborative Committee of Clinical Informatization in Diabetes Mellitus (by the Japan Diabetes Society and the Japan Association for Medical Informatics) with the Collaborative Initiative by additional four Japanese clinical associations (the Japanese Society of Laboratory Medicine, the Japanese Society of Hypertension, the Japanese Society of Nephrology and the Japan Atherosclerosis Society). The article has been jointly published in Diabetology International and Journal of Diabetes Investigation (https://doi.org/10.1111/ jdi.13043) by the Japan Diabetes Society.
Funding Information:
We thank the former members of the CCCIDM, including Professor Emeritus Naoko Tajima, Dr. Shinji Kagimoto, Prof. Shinsuke Fujita, Prof. Syunji Wakamiya, and Prof. Masaki Miyamoto for their contributions to establishing the CISs and SMISs. We also thank the six participating associations (JDS, JAMI, JSH, JAS, JSN, and JSLM) and observers from the associations, and the offices of the JDS and JAMI for supporting the CCCIDM and CEC activities. We appreciate the consistent support by the Japanese Cabinet Secretariat in developing SMISs through the CEC meeting. Furthermore, we thank the MEDIS-DC for supporting the CEC meeting as part of the ?Research project on standardization and establishment of a business model for preventing aggravation of lifestyle-related diseases in cooperation with the medical insurers, disease management companies, and medical institutions,? which is funded by AMED.
Publisher Copyright:
© 2019, The Japan Diabetes Society.
PY - 2019/4/15
Y1 - 2019/4/15
N2 - It is expected that a large amount of data related to diabetes and other chronic diseases will be generated. However, databases constructed without standardized data item sets can be limited in their usefulness. To address this, the Collaborative Committee of Clinical Informatization in Diabetes Mellitus was established in 2011 by the Japan Diabetes Society and Japan Association for Medical Informatics. The committee has developed core item sets and self-management item sets for diabetes mellitus, hypertension, dyslipidemia, and chronic kidney disease incollaboration with the Japanese Society of Hypertension, Japan Atherosclerosis Society, Japanese Society of Nephrology, and Japanese Society of Laboratory Medicine, as well as a mapping table that aligns the self-management item sets with the Japanese standardized codes for laboratory testing. The committee also determined detailed specifications for implementing the four self-management item sets in personal health record applications to facilitate risk stratification, the generation of alerts using information and communications technology systems, the avoidance of data input errors, and the generation of reminders to input the self-management item set data. The approach developed by the committee may be useful for combining databases for various purposes (such as for clinical studies, patient education, and electronic medical record systems) and for facilitating collaboration between personal health record administrators.
AB - It is expected that a large amount of data related to diabetes and other chronic diseases will be generated. However, databases constructed without standardized data item sets can be limited in their usefulness. To address this, the Collaborative Committee of Clinical Informatization in Diabetes Mellitus was established in 2011 by the Japan Diabetes Society and Japan Association for Medical Informatics. The committee has developed core item sets and self-management item sets for diabetes mellitus, hypertension, dyslipidemia, and chronic kidney disease incollaboration with the Japanese Society of Hypertension, Japan Atherosclerosis Society, Japanese Society of Nephrology, and Japanese Society of Laboratory Medicine, as well as a mapping table that aligns the self-management item sets with the Japanese standardized codes for laboratory testing. The committee also determined detailed specifications for implementing the four self-management item sets in personal health record applications to facilitate risk stratification, the generation of alerts using information and communications technology systems, the avoidance of data input errors, and the generation of reminders to input the self-management item set data. The approach developed by the committee may be useful for combining databases for various purposes (such as for clinical studies, patient education, and electronic medical record systems) and for facilitating collaboration between personal health record administrators.
UR - http://www.scopus.com/inward/record.url?scp=85065143562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065143562&partnerID=8YFLogxK
U2 - 10.1007/s13340-019-00389-7
DO - 10.1007/s13340-019-00389-7
M3 - Article
C2 - 31020808
AN - SCOPUS:85065143562
VL - 10
SP - 85
EP - 92
JO - Diabetology International
JF - Diabetology International
SN - 2190-1678
IS - 2
ER -